Ano Pharma and Roche will conduct clinical trials with PD-L1 monoantigen "T-drugs"

On December 4, 2020, Adlai Nortye Pharmaceuticals, a global biopharmaceutical company focused on oncology immunotherapy, announced a clinical cooperation agreement with Roche Pharmaceuticals, which will work with Adlai Pharmaceuticals to develop Phase I clinical trials of NOMA AN2025 (PI3K inhibitors), AN0025 (EP4 antagonists) and Rochezolizumab (Tencentriq®, Atiliju monoanti).
This phase I clinical trial of the combined drug, AN2025S0101, is a one-arm open, multi-center, phase I dose exploration study to assess the safety, toerability, and pharmacodynamics of AN2025 and AN0025 in patients with local late stage/metastasis solid tumors.
, the initial efficacy of these combined treatments will be evaluated.
the main purpose of this study was to determine the appropriate dose for both dose-limiting toxicity (DLT) and at the same time as attilijudant.
the study included three restrictive toxicity (DLT) observation cycles, each of which will maintain a 21-day treatment cycle.
the study is expected to recruit 12-63 subjects, all of the patients in the group will be treated with a combined drug until the course of the disease progresses, either to produce insatiable toxicity, or to withdraw from the clinic.
clinical trial will begin in the United States and other regions.
the agreement, Roche Pharmaceuticals will provide acetic monoantigen for the clinical trial.
"We are excited to work clinically with Roche, the world's leading pharmaceutical company, and we look forward to delivering innovative therapies to patients with solid tumors worldwide through combination drug use."
Dr. Lars Birgerson, of Ano Pharmaceuticals, said the clinical collaboration with Roche involves two core products in the Arno pipeline and has the potential for a global "first in class."
looks forward to involving Ano Pharma in a global wave of innovation in oncology immunotherapy by exploring a joint clinical trial of AN2025, AN0025 and Roche's PD-L1 inhibitor Tecentriq.
is a global biopharmaceutical company at the clinical stage dedicated to the development of differentiated and innovative cancer immunotherapy drugs.
vision of Ano Pharmaceuticals is to turn cancer into a truly chronic disease by exploring 'cocktail' therapies that once again increase the effectiveness and cure rate of combination drugs on the basis of targeting and immunotherapy.
through collaboration with the world's leading pharmaceutical and biotechnology companies and in-house research and development, Ano Pharma has established a pipeline with oncology immunotherapy as its core, covering more than a dozen targets.
Currently, Ano Pharma has three clinical phase products and is rapidly conducting clinical trials around the world under the leadership of a world-class team, including the AN2025 (Buparlisib) program, which has been qualified by the FDA as a fast track and has entered the Global Phase III clinical trial of metastatic head and neck cancer disease; The leading intravenously administered lysosovirus AN1004 (Pelareorep) project is entering phase III of the Global Multi-Center Clinic, and the global potential FIC Oncology ImmunoAN0025 (EP4 antagonist) project is currently in clinical phase IB in europe and the United States.
With this clinical partnership with Roche, Ano Pharma has become one of the few pharmaceutical companies in China to achieve strategic cooperation with two of the world's pharmaceutical giants, and in addition to this partnership with Roche, Ano and Mercado's global multi-center Phase IB clinical trial in AN0025 with Keytruda® is also under way.
。